Instrumento Inactivo

Otros idiomas Acura Pharmaceuticals, Inc. Other OTC

Acciones

ACUR

US00509L8028

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	26/03
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	26/03
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	14/03
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	14/02
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	14/02
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	21/12
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	21/12
Acura Pharmaceuticals : New Financial Obligation - Form 8-K	06/12
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	25/09/23
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	31/08/23
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	30/08/23
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K	16/08/23
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	16/08/23
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	28/07/23
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/06/23
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	30/06/23
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30/06/23
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	28/06/23
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	28/06/23
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC	26/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Acura Pharmaceuticals, Inc. Other OTC

Acciones

ACUR

US00509L8028

Otros idiomas

Filtros